- VT-1953 treatment over 14 days resulted in highly statistically significant improvements in bad smell or malodor associated with malignant fungating wound (primary endpoint) (P = 0.002).
- Patient-reported impact of bad smell or malodor on quality of life (secondary endpoint) improved significantly (P = 0.0256), as did wound pain reduction (P = 0.002)
- VT-1953 was well-tolerated, with no new safety concerns observed.
- Based on these positive Phase 2 results, the company plans to advance VT-1953 into a pivotal study following discussions with the FDA to seek approval to enter $1B potential addressable market opportunity.
Vyome Holdings, Inc. (“Vyome”) (Nasdaq: HIND) announced the final results from an investigator-initiated Phase 2 proof of concept study of VT-1953 topical gel in people with malignant fungating wounds (“MFW”). VT-1953, a first-in-class immunomodulator for this indication, achieved both its primary and secondary endpoints. With this result, Vyome plans to advance to Phase III pivotal trial, seek FDA approval, and enter the $1B potential addressable market as the only anticipated approved solution for malignant fungating wounds.
“These are exciting results for Vyome, both in our primary and secondary endpoints. Inflammation is one of the greatest problems in the world today, and our study on malignant fungating wounds showed that those who received our drug VT-1953 had significant and rapid improvements in symptoms, quality of life, and emotional and physical functions. These positive results give us high confidence as we design a very cost-efficient pivotal study for FDA approval and a real opportunity to solve an important unmet need, a billion-dollar addressable market opportunity,” said Dr. Shiladitya Sengupta, co-founder and director of Vyome and Associate Professor of Medicine at Harvard Medical School.
MFW is a debilitating condition that occurs in 5-14% of advanced cancer patientsi. It is estimated that there are over 693,000 patients with advanced cancer in the US alone and approximately 10M globally. Cancer cells break through the skin and cause a chronic wound (MFW), which is extremely distressing to patients, given the high burden of symptoms, including extreme bad smell, severe pain, a feeling of shame, low self-esteem, and social isolationii.
On the primary endpoint of bad smell or malodor scored by the investigator, patients treated with VT-1953 achieved a statistically significant improvement (P=0.002) from what was a very severe bad smell at baseline to a much milder smell within just 14 days of treatment. The improvement at the end of 14 days seen with VT-1953 was statistically significant (P=0.0015) compared with vehicle-treated patients. A statistically significant improvement was seen with VT-1953 as early as Day 7 (P=0.015). VT-1953 was well-tolerated by patients.
On the secondary endpoint of patient-reported impact of bad smell on the quality of life, VT-1953 resulted in a statistically significant improvement (P=0.0256) compared to vehicle-treatment by Day 14. Patients treated with VT-1953 also reported a clinically significant improvement in pain symptoms (exploratory endpoint) by Day 14 (P=0.002 compared with baseline; P=0.0026 vs vehicle-treated patients). On a patient-reported Quality of life component score (exploratory endpoint), treatment with VT-1953 resulted in a significant improvement by Day 14 (P=0.002) compared to baseline and vs vehicle-treatment (P=0.0032).
Venkat Nelabhotla, CEO of Vyome, stated that “these positive results reinforce the potential of VT1953, and we are now preparing to engage with the FDA to design and initiate a pivotal Phase III clinical study in 2026. Over the past several months, we have strengthened our team with top-tier clinical, regulatory, and scientific leaders who bring deep experience in advancing differentiated therapies. This positions us well for disciplined execution as we move into the next phase of development. Vyome remains well capitalized through 2026, allowing us to advance VT1953, a potentially orphan designation program, as a part of our broader chronic immune-inflammation portfolio. We look forward to progressing this program thoughtfully and responsibly toward its next key milestones.”
The global immune-inflammatory market size is expected to reach USD 431.11 billion by 2033, growing at a CAGR of 8.2% from $212 billion in 2024iii.
Chief Executive Officer Venkat Nelabhotla provides a video update (see the link below) discussing the positive results of the Phase 2 study of VT-1953 and plans for the future.
About Vyome Holdings, Inc.
Vyome is building the world’s premier platform spanning the US-India innovation corridor. Based in Cambridge, MA, Vyome’s immediate focus is on leveraging its clinical-stage assets to transform the lives of patients with immuno-inflammatory conditions. By applying groundbreaking science and its unique positioning across the US-India innovation corridor, Vyome seeks to deliver lasting value to shareholders in a hyper cost-efficient manner while upholding global standards of quality and safety. To learn more, please visit www.vyometx.com
Forward-Looking Statements
Certain statements made in this press release are “forward-looking statements” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by the use of words such as “target,” “believe,” “expect,” “will,” “shall,” “may,” “anticipate,” “estimate,” “would,” “positioned,” “future,” “forecast,” “intend,” “plan,” “project,” “outlook”, and other similar expressions that predict or indicate future events or trends or that are not statements of historical matters. Such statements, include, but are not limited to, statements contained in this press release relating to Vyome’s business strategy, Vyome’s future operating results and liquidity and capital resources outlook. Forward-looking statements are based on Vyome’s current expectations and assumptions regarding Vyome’s business, the economy and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict. Vyome’s actual results may differ materially from those contemplated by the forward-looking statements. They are neither statements of historical fact nor guarantees of assurance of future performance. Vyome cautions you, therefore against relying on any of these forward-looking statements. Important factors that could cause actual results to differ materially from those in the forward-looking statements include, without limitation, Vyome’s ability to raise capital to fund continuing operations; our ability to protect Vyome’s intellectual property rights; the impact of any infringement actions or other litigation brought against Vyome; competition from other providers and products; Vyome’s ability to develop and commercialize products and services; changes in government regulation; Vyome’s ability to complete capital raising transactions; and other factors relating to Vyome’s industry, operations and results of operations. Actual results may differ significantly from those anticipated, believed, estimated, expected, intended, or planned. Factors or events that could cause Vyome’s actual results to differ may emerge from time to time, and it is not possible for Vyome to predict all of them. Vyome cannot guarantee future results, levels of activity, performance, or achievements. Vyome assumes no obligation to update any forward-looking statements in order to reflect any event or circumstance that may arise after the date of this release, except as may be required under applicable securities law.
Visit us on social media:
iVardhan M, et al. The Microbiome, Malignant Fungating Wounds, and Palliative Care. Front Cell Infect Microbiol. 2019;9:373. doi: 10.3389/fcimb.2019.00373
iiAlexander, S.J. An intense and unforgettable experience: the lived experience of malignant wounds from the perspectives of patients, caregivers and nurses. International Journal of Woundcare. 2010, 7:456-465
iii https://www.datamintelligence.com/research-report/immunology-and-inflammatory-diseases-drugs-market
View source version on businesswire.com: https://www.businesswire.com/news/home/20251208813165/en/
